Louie, Michael J.

Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 988

Sex Differences in the Use of Statins in Community Practice: Patient and Provider Assessment of Lipid Management Registry

Nanna, M. G., Wang, T. Y., Xiang, Q., Goldberg, A. C., Robinson, J. G., Roger, V. L., Virani, S. S., Wilson, P. W. F., Louie, M. J., Koren, A., et al. (2019) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthSex and Gender in Healthcare

Cited by 313

Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry

Bradley, C. K., Wang, T. Y., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S. S., Louie, M. J., Lee, L. V., Peterson, E. D., et al. (2019) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 286

Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

Nissen, S. E., Menon, V., Nicholls, S. J., Brennan, D., Laffin, L., Ridker, P., Ray, K. K., Mason, D., Kastelein, J. J. P., Cho, L., et al. (2023) · JAMA

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 146

Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial

Ray, K. K., Nicholls, S. J., Li, N., Louie, M. J., Brennan, D., Lincoff, A. M., & Nissen, S. E. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 99

Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry

Nanna, M. G., Navar, A. M., Wang, T. Y., Mi, X., Virani, S. S., Louie, M. J., Lee, L. V., Goldberg, A. C., Roger, V. L., Robinson, J., et al. (2018) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthPharmaceutical Practices and Patient Outcomes

Cited by 82

Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials

Ray, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 69